SCHEMBL5248504

SCHEMBL5248504

C(=C/c1ccccc1OCCCOC1CCCCO1)\c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
KDM4C Q9H3R0 1/20 0.44
NFE2L2 Q16236 3/20 0.43
TRPA1 O75762 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CHRNA7 P36544 2/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA10 Q9GZZ6 1/20 0.35
CHRNA9 Q9UGM1 1/20 0.35
MGLL Q99685 1/20 0.35
ALDH1A1 P00352 3/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A1 P04798 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5248508 1.00 MEN1 (0.47) MEN1KMT2AKDM4CNFE2L2TRPA1
SCHEMBL5249245 0.84 KMT2A (0.50) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL8350940 0.79 MEN1 (0.50) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL8497259 0.79 MEN1 (0.50) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL6099052 0.79 KMT2A (0.49) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL10051458 0.79 KDM4C (0.44) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL12634797 0.78 ALDH1A1 (0.55) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL3446617 0.77 MEN1 (0.46) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL28619035 0.76 MEN1 (0.52) MEN1KMT2AKDM4CL3MBTL1NPC1
SCHEMBL9335071 0.76 KMT2A (0.61) MEN1KMT2AKDM4CL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1260512-B1 NOVEL CYCLIC AMIDE DERIVATIVES MITSUBISHI PHARMA CORP (JP) 2007-07-04 EP disclosed
US-7166617-B2 Cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-01-23 US disclosed
US-20030212094-A1 Novel cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2003-11-13 US disclosed
EP-1260512-A1 NOVEL CYCLIC AMIDE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2002-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212094-A1 Novel cyclic amide derivatives SIGMAR1, OPRM1, OPRD1 MEN1 4834/4885KMT2A 2651/4885KDM4C 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.